Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jana Portnow

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|October 26, 2010
Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug developmentJaishri Blakeley, Jana Portnow
Journal of the National Comprehensive Cancer Network : JNCCN|September 19, 2009
Assessment of pain caused by invasive procedures in cancer patientsJana Portnow, Christine Lim, Stuart A Grossman
Neuro-Oncology|September 14, 2023
NCCN CNS tumor guidelines update for 2023Burt Nabors, Jana Portnow, Jona Hattangadi-Gluth, et al.
Neuro-Oncology|December 18, 2024
NCCN CNS Tumor Guidelines Update for 2024Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, et al.
Neuro-Oncology|January 5, 2002
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomasJana Portnow, Samia Suleman, Stuart A Grossman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiationJana Portnow, Behnam Badie, Mike Chen, et al.
Journal of Neuro-Oncology|March 18, 2014
A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agentJana Portnow, Behnam Badie, Xueli Liu, et al.
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2024
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumorsZeynep Eroglu, Timothy Synold, Behnam Badie, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2013
A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasJana Portnow, Behnam Badie, Susan Markel, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|October 26, 2010
Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug developmentJaishri Blakeley, Jana Portnow
Journal of the National Comprehensive Cancer Network : JNCCN|September 19, 2009
Assessment of pain caused by invasive procedures in cancer patientsJana Portnow, Christine Lim, Stuart A Grossman
Neuro-Oncology|September 14, 2023
NCCN CNS tumor guidelines update for 2023Burt Nabors, Jana Portnow, Jona Hattangadi-Gluth, et al.
Neuro-Oncology|December 18, 2024
NCCN CNS Tumor Guidelines Update for 2024Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, et al.
Neuro-Oncology|January 5, 2002
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomasJana Portnow, Samia Suleman, Stuart A Grossman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiationJana Portnow, Behnam Badie, Mike Chen, et al.
Journal of Neuro-Oncology|March 18, 2014
A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agentJana Portnow, Behnam Badie, Xueli Liu, et al.
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2024
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumorsZeynep Eroglu, Timothy Synold, Behnam Badie, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2013
A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasJana Portnow, Behnam Badie, Susan Markel, et al.
Pageof 5